Journal article

Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database

Pal Moller, Toni Seppala, Inge Bernstein, Elke Holinski-Feder, Paola Sala, D Gareth Evans, Annika Lindblom, Finlay Macrae, Ignacio Blanco, Rolf Sijmons, Jacqueline Jeffries, Hans Vasen, John Burn, Sigve Nakken, Eivind Hovig, Einar Andreas Rodland, Kukatharmini Tharmaratnam, Wouter H de Vos Tot Nederveen Cappel, James Hill, Juul Wijnen Show all

GUT | BMJ PUBLISHING GROUP | Published : 2017

Abstract

OBJECTIVE: Today most patients with Lynch syndrome (LS) survive their first cancer. There is limited information on the incidences and outcome of subsequent cancers. The present study addresses three questions: (i) what is the cumulative incidence of a subsequent cancer; (ii) in which organs do subsequent cancers occur; and (iii) what is the survival following these cancers? DESIGN: Information was collated on prospectively organised surveillance and prospectively observed outcomes in patients with LS who had cancer prior to inclusion and analysed by age, gender and genetic variants. RESULTS: 1273 patients with LS from 10 countries were followed up for 7753 observation years. 318 patients (2..

View full abstract

Grants

Awarded by Spanish Ministry of Economy and Competitiveness


Awarded by RTICC


Awarded by Government of Catalonia


Awarded by Cancer Research UK


Awarded by National Institute for Health Research


Awarded by Cancer Foundation Finland sr


Funding Acknowledgements

The Finnish contribution was supported by The Finnish Cancer Foundation, The Sigrid Juselius Foundation, Mary and Georg Ehrnrooth foundation and State Research Funding. D Gareth Evans is an NIHR senior investigator. Mark Jenkins has a Fellowship from the National Health and Medical Research Council of Australia. The Spanish contribution has been funded by the Spanish Ministry of Economy and Competitiveness SAF2012-33636, SAF2015-68016-R (GC, MP); the Carlos III Health Institute; RTICC (RD12/0036/0031); the Scientific Foundation Asociacion Espanola Contra el Cancer; and the Government of Catalonia (2014 SGR 338) and the Welsh Contribution by the Wales Gene Park. The Swedish contribution was supported by the Swedish Cancer Society, the Swedish Research Council and the Stockholm Cancer Society.